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CYCLOSPORINE A (CSA) SIGNIFICANTLY REDUCES THE CYTOTOXIC EF-
FECTS OF IN VITRO EXPANDED NK CELLS: IMPLICATIONS FOR ADOP-
TIVE NK CELL THERAPY IN THE SETTING OF ALLOGENEIC
HEMATOPOIETIC STEM CELL (HCT) TRANSPLANTATION
Yokoyama, H.1, Berg, M.1, Lundqvist, A.1, McCoy, J.P.2,
Srivastava, S.1, Smith, A.1, Childs, R.1. 1NHLBI, NIH, Bethesda,
MD; 2NHLBI, NIH, Bethesda, MD.
Recently, clinical trials have evaluated the impact of infusing nat-
ural killer (NK) cells following HCT). The impact of CSA, com-
monly used to prevent GVHD after HCT, on adoptive NK cell
function is unkown Hong et al reported the phenotype and function
of fresh NK cells was altered by CSA, showing CSA treated NK
cells elicited enhanced cytotoxicity against tumor targets. However,
the impact of CSA on in vitro expanded NK cell function and phe-
notype has not been explored. We analyzed the impact of culturing
fresh and in vitro expanded NK cells in physiological doses of CSA
(40, 200, 1000 ng/ml for 18 hrs)Fresh NK cells were obtained from
peripheral blood mononuclear cells of healthy donors using immu-
nomagnetic beads to isolate CD561/CD3- cells. NK cell expansion
in vitro was maximized by using irradiated EBV transformed B cells
as feeder cells in media containing IL-2 [500U/ml] for 12–14 days.
Compared to controls, CSA treated fresh NK cells had a significant
reduction in IL2-induced proliferation (stimulation index 0.51 6
0.1) and decreased TRAIL expression (MFI 17.3 vs 10.9, p 5
0.023). Furthermore, an ELISA assay showed fresh NK cells treated
with CSA had a significant reduction in IL-2 induced IFN-g pro-
duction (median 231 vs 57 pg/ml, p 5 0.025). In vitro expanded
NK cells cultured in CSA also showed a reduction in IL-2-induced
TRAIL expression (MFI 26.2 vs 16.3). Cytotoxicity assays showed
that at the highest dose of CSA (1000 ng/ml), freshly isolated NK
cells maintained their ability to kill K562 targets. In contrast, ex-
panded NK cells cultured in CSA for 18 hours with or without
IL-2 compared to controls had a significant reduction in the killing
of K562 cells (E:T 5 10:1, median 66 vs 43% lysis, p 5 0.011) and
RCC cells (E:T5 20:1, 78.5 vs 38.5% lysis). These data show CSA
alters the phenotype and function of both fresh and expanded NK
cells. More importantly, these experiments show NK cell TRAIL
mediated killing of tumor targets is significantly reduced when ex-
panded NK are exposed to physiologic doses of CSA in vitro. These
findings suggest the anti-tumor effects of in vitro expanded NK cells
could be hindered when adoptively infused in HCT patients receiv-
ing CSA.391
RITUXIMAB INFUSION AFTER ALLOGENEIC HCT PREVENTS DONOR B
CELL RECONSTITUTION AND ALLOIMMUNITY ONE YEAR POST TRANS-
PLANT
Sahaf, B.1, Chen, G.1, Boiko, J.1, Heydari, K.2, Arai, S.1, Miklos, D.1.
1Blood and Marrow Transplant, Stanford, CA; 2Pediatric Stem Cell
Transplant, Stanford, CA.
B cells are implicated in chronic graft-vs-host disease (cGVHD)
and anti-B cell rituximab is effective cGVHD therapy. We hypoth-
esize post allo-HCT rituximab therapy will prevent chronic
GVHD. Thirty-five MCL and CLL patients conditioned with non-
myeloablative total lymphoid irradiation and anti-thymocyte glob-
ulin (TLI-ATG) conditioning received rituximab 375 mg/m2 56,
63, 70, and 77 after allogeneic HCT.
Peripheral B cells are normal in number and of donor origin 3
months after TLI-ATG allo- HCT. With rituximab addition, pe-
ripheral CD191 B cells remained undetectable 9 months after
transplant; were first detected in 6/11 patients at 1 year and 8/8 pa-
tients at 1.5 years. These cells predominately expressed a memory
phenotype (CD191CD271, n 5 6). Hi-Dimension 12-color
FACS analysis of bone marrow aspirates collected day 56 (pre-ritux-
imab), 90, 180 and 365 days post-HCT showed lymphoid progen-
itors were prevalent days 56 and 90 (20–40%) and decline to 3–8%
of the lymphocytes, 365 days after HCT. Second, mature IgD1CD191 B cells are present day 56 pre-rituximab. Plasma cells are
unchanged throughout.
Plasma IgG levels decreased to 60% pre transplant levels at 6
months and 78% at one year. At 6, 9, and 12 months, EBV titer
was 76%, 104%, and 103% relative to pretransplant patient titers
demonstrating protective antibodies are maintained despite rituxi-
mab therapy presumably secreted from long-lived recipient CD20
negative plasma cells. Similar results are seen for tetanus. Our stron-
gest support for persistent recipient plasma cell immunity is allotype
discrimination of donor and recipient IgG2 showing the absence of
donor antibody development 1.5 years post-HCT. Further sup-
porting this, no allogeneic antibody responses have developed in
the five male with female donors against H-Y antigens.
In summary, rituximab therapy 2 months after allo-HCT pre-
vents donor B cell reconstitution one year after HCT, but protec-
tive recipient humoral immunity persists. Chronic GVHD
assessment requires further follow-up, but is promising.
Lymphoid Mature PlasmaDays after
HCTProgenitors
(CD341
CD1171)
(Pro B Cell
CD191CD341
CD10-)
(Pre B Cells
CD34-CD101
CD191)B Cells
(CD191
IgD1IgM1) CCells
(CD381
D1381)Total
IgG56, n 5 6
(Pre-ritux)22–25% 2–6% 0.1–4% 0.2–1% 0.7–1% 655 ug/dl
81% pre90, n 5 4 20–40% 2–9% 0.5–1.7% Not detected 0.5–3% 910 ug/dl
101% pre180, n 5 5 13–20% 5–12% 0.7% 1% 0.5–2% 507 ug/dl
60% pre365, n 5 5 3–8% 2–10% 0–0.5% 1–5% 0.5–3.7% 642 ug/dl
78%% range of cells gated on total lymphocytes; Not detected: within
the range of error for the measurement.392
DELAYED RECOVERY OF MYELOID (mDC) AND PLASMACYTOID (pDC)
DENDRITIC CELLS AT 3 MONTHS AFTER ALLOGENEIC HSC TRANSPLAN-
TATION CORRELATES WITH AN INCREASED TRANSPLANT-RELATED
AND OVERALL MORTALITY INDEPENDENTLY OF GVHD
Arpinati, M.1, Chirumbolo, G.1, Nicolini, B.1, De Vivo, A.1,
Bonifazi, F.1, Giannini, M.B.1, Giovannini, M.1, Bandini, G.1,
Martelli, V.1, Stanzani, M.1, Baccarani, M.1, Rondelli, D.2. 1University
of Bologna, Bologna, Italy; 2University of Illinois at Chicago, Chicago, IL.
Background: A low number of antigen presenting cells (APC) in
the peripheral blood 1 month after allogeneic HSC transplantation
has been previously associated with increased mortality. However,
the impact of APC recovery at later time points (3 through 12
months) after transplant has not been thoroughly investigated.
Aim: In this study we analyzed the factors affecting APC recovery
between 3 and 12 months after allogeneic HSC transplant and de-
termined its impact on the clinical outcome. Patients and
Methods: Blood samples from all patients undergoing an alloge-
neic HSC transplant in our institution from June 1999 through
June 2006 were analyzed. PB numbers of CD11c1 mDC,
CD1231 pDC and CD141 monocytes were determined based
on flow cytometry at 3 (n 5 161), 6 (n 5 127) and 12 months (n
5 80) after transplant. Results: Median numbers of PB APC at 3
months after transplant were (x106/L): mDC (7.4), pDC (2.5) and
monocytes (254), and then increased gradually at 6 (mDC 9.2,
pDC 3.4, monocytes 272) and 12 months (mDC 11.3, pDC 4.6,
monocytes 335). mDC recovery was delayed both at 3 and 6 months
in patients with advanced disease at transplant (p\ 0.00001 and
0.003, respectively), and acute GVHD grade II-IV (p 5 0.00009
and 0.01). Similarly, pDC recovery was delayed at 3 and 6 months
in patients with advanced disease (p 5 0.0001 and p 5 0.003) and
acute GVHD (p 5 0.0004 and p 5 0.02). Moreover, both mDC
and pDC levels at 6 months were reduced in patients with extensive
chronic GVHD (p 5 0.001 and p 5 0.0007 respectively). All other
analysed factors did not correlate with mDC and pDC recovery.
Also, mDC and pDC numbers at 12 months, as well as monocyte
Poster Session II 143numbers at any time point, did not correlate with any of the analysed
factors. Lower numbers of mDC and pDC in the PB at 3 months
after transplant significantly correlated with increased overall and
transplant-related mortality in univariate analysis. In multivariate
analysis low mDC counts correlated with increased overall mortal-
ity (p 5 0.008) whereas low pDC counts correlated with increased
TRM (p 5 0.07). PB Monocyte numbers instead did not correlate
with any of the analysed end points. Conclusion: Recovery of
mDC and pDC 3–12 months after transplant was reduced in pa-
tients with advanced disease at transplant, or developing acute or
chronic extensive GVHD after transplant. Nevertheless, a delayed
recovery of mDC and pDC within 3 months after transplant was
an independent factor contributing to a greater mortality.393
PRESENCE OF ACTIVATING KIR GENOTYPES INFLUENCES CYTOMEGA-
LOVIRUS (CMV) REACTIVATION AS DETECTED BY Q-PCR IN HCT RECIP-
IENTS
Sun, J.1, Gallez-Hawkins, G.M.2, Thao, L.2, Li, X.2, Franck, A.E.2,
Dagis, A.3, Senitzer, D.1, Forman, S.J.1, Zaia, J.A.2. 1City of Hope,
Duarte, CA; 2Beckman Research Institute of City of Hope, Duarte,
CA; 3City of Hope, Duarte, CA.
Killer Ig-like receptor (KIR) is a cluster of natural killer cell re-
ceptors presented by T cells and natural killer (NK) cells. The com-
patibility of these receptors between the donor and the recipient
plays a role in hematopoietic cell transplantation (HCT) for either
activating (aKIR) or inhibitory KIRs. Some aKIRs bind only weakly
to HLA class I and the natural ligands remain undetermined
whereas the inhibitory KIRs bind HLA class I molecules with spec-
ificity for defined alleles of HLA-C, HLA-B, or HLA-A. It has been
suggested that the donor KIR genotype influences the rate of CMV
infection and, more particularly, that aKIR genes are inversely asso-
ciated with CMV reactivation (Cook et al Blood 2006; 107: 1230–
32; Chen et al. BMT 2006; 38: 437–44). In this study, a cohort of
92 non T-cell depleted subjects, who had received a matched unre-
lated or HLA identical related donor, were analyzed for inhibitory
KIR ligands and KIR genotypes obtained using a multiplex PCR-
SSP method. All recipients were at risk for CMV reactivation which
was monitored bi-weekly by Q-PCR on plasma DNA.
Results: Two groups, those with CMV reactivation (n 5 68) vs
No CMV (n 5 24), were compared for the presence of KIR deter-
minants and analyzed using a contingency table with Chi2 test for
probability values. An increased number of aKIR genes in the do-
nor, either involving an A haplotype, carrying a single aKIR gene,
or the AB and BB haplotypes carrying more than one aKIRs, was
significantly associated with a reduction of CMV reactivation (p
5 0.0438). In addition, using a previously described algorithm for
scoring KIR determinants in donor and recipient (Sun et al. BMT
2005; 56: 525–530), values .0, associated with more aKIRs in the
donor but not in the recipient, were associated with significantly
less CMV reactivation (62% VS 85%, p5 0.0372). When the recip-
ients were analyzed for HLA-Cw KIR ligand group1 or 2, there was
no significant association with CMV reactivation. This was still true
when HLA class I mismatched donor-recipient pairs were excluded.
Conclusion: In the HCT setting, aKIR genes in donor cells protect
the recipient from CMV reactivation but the HLA-Cw allotype of
the recipient does not predict CMV infection.394
VACCINATION WITH CARNARYPOX PP65 CMV VACCINE INDUCES RELI-
ABLE CD41 AND CD81 T CELL RESPONSES ONLY IN INDIVIDUALS
WHO LACK BASELINE RESPONSES. IMPLICATIONS FOR DONOR VACCI-
NATION TO BOOST CMV IMMUNITY IN STEM CELL TRANSPLANT RECIP-
IENTS
Shenoy, A.1, Solomon, S.2, Pichon, S.3, Cadoz, M.3, Barrett, A.J.1.
1NIH, Bethesda, MD; 2The Blood and Marrow Transplant Program,
Atlanta, GA; 3Sanofi Pasteur, Marcy L’etoile, France.CMV reactivation after allogeniec stem cell transplant (SCT) re-
mains a major cause of post-transplant morbidity but may be miti-
gated by strong T-cell responses in the transplanted donor T-cell
repertoire. We vaccinated 25 subjects with ‘‘ALVAC pp-65’’ (sanofi
pasteur, Lyon, France) to boost CMV responses in seropositive sub-
jects and induce CMV responses in seronegative subjects. An accel-
erated regimen giving 1.0 ml ALVAC pp-65 on days 0 and 5 to
seropositive subjects and days 0, 5, and 10 to seronegative individ-
uals was used. CD41 and CD81 T-cell responses to a CMV
pp65 peptide library were measured at serial timepoints post vacci-
nation using flow cytometry to identify interferon-gamma produc-
ing T-cells. Positive responses were defined as a twofold increase of
interferon-gamma production compared to unstimulated cells. Of
the 25 subjects analyzed, 13 were seropositive and 12 were seroneg-
ative. As previously reported, serostatus did not correlate with base-
line CD41 and CD81 CMV response. Indeed there were no
differences in T-cell response patterns according to serostatus.
We therefore segregated subjects into baseline CD41 or CD81 re-
sponders or non-responders irrespective of serostatus. Six of 9
CD41 non-responders had a 2–8 fold (median 4) increase in re-
sponse by day 5. In contrast, 13 of 16 subjects with a baseline
CD4 response (identified by a stimulation index of $2 at baseline)
showed decreased or undetectable responses at day 5 with variable
responses thereafter. Nine of 11 CD81 non-responders had a 2–9
fold (median 3) response by day 5. In contrast, 10 of 14 CD81 re-
sponders showed decreased response by day 5 with variable re-
sponses thereafter. Apart from pain at the injection site, vaccine
was well tolerated. These results show that ALVAC is a well toler-
ated vaccine with the potential to induce pp65 responses in subjects
who lack baseline responses. In subjects that have baseline re-
sponses, vaccination appears to dampen immediate immune re-
sponse. It is unclear if the vaccine is inducing tolerance in these
individuals and if this is related to dose of the vaccine. ALVAC
pp65 can elicit quick responses of varying duration in subjects
that lack CD4 or CD81T cell responses to CMV and could there-
fore be used to improve the transfer of CMV immunity to SCT re-
cipients using such donors. However, in donors that have a baseline
CMV response, vaccination may be detrimental to the recipients’
ability to respond to CMV.395
IMPACT OF DONOR T CELLS ON B CELL DEVELOPMENT AFTER HEMA-
TOPOIETIC CELL TRANSPLANTATION: LESSONS FROM B CELL DEFI-
CIENT MICE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Tung, J.W.3,
Shizuru, J.A.1. 1Stanford School of Medicine, Stanford, CA; 2University
Medical Center, Freiburg i.Br., Germany; 3Stanford School of Medicine,
Stanford, CA.
Allogeneic hematopoietic cell transplant (HCT) recipients often
exhibit B cell (BC) lymphopenia due, in part, to graft-versus-host-
disease (GVHD). Here, we studied the influence of donor T cells
(TC) on BC deficiency post-HCT. Following lethal irradiation,
BALB. B mice were given FACS purified hematopoietic stem cells
(HSC: cKIT1Thy1.1loLin-Sca-11) alone, or with co-transfer of
whole splenocytes (SP), CD4 or CD8 TCs from minor antigen-
mismatched C57BL/6 (B6) mice. When pure HSC were trans-
planted, BC reconstituted promptly (median 33% of lymphocytes
[d30]; 61% [d60]; 74% [d90]), whereas TC engraftment was re-
tarded and did not achieve full donor chimerism. In contrast, addi-
tion of SP or CD4 TCs substantially suppressed BC reconstitution,
correlating with the degree of acute GVHD, and TC transfer ad-
vanced TC engraftment and resulted in early conversion to full do-
nor chimerism. To test if previous events in the donor sensitize TCs
against BC structures, thereby promoting anti-BC cytotoxicity
post-HCT, TCs from B cell deficient mMT B6 mice were co-trans-
planted with wild type (WT) HSC. Remarkably, BC engraftment
was completely prevented through d90. TCs regenerated faster,
but the vast majority originated from spleen and not HSC. To dif-
ferentiate this lack of BC engraftment from GVHD-associated al-
loreactive BC lymphopenia, syngenic B6 recipients were used.
Again, initially complete blockade of BC engraftment was observed,
although this suppression was overcome earlier post-HCT as
